These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30766446)

  • 1. iNKT Cell Activation Exacerbates the Development of Huntington's Disease in R6/2 Transgenic Mice.
    Park HJ; Lee SW; Im W; Kim M; Van Kaer L; Hong S
    Mediators Inflamm; 2019; 2019():3540974. PubMed ID: 30766446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The iNKT cell ligand α-GalCer prevents murine septic shock by inducing IL10-producing iNKT and B cells.
    Park YH; Lee SW; Kim TC; Park HJ; Van Kaer L; Hong S
    Front Immunol; 2024; 15():1457690. PubMed ID: 39355237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-galactosylceramide pre-treatment attenuates clinical symptoms of LPS-induced acute neuroinflammation by converting pathogenic iNKT cells to anti-inflammatory iNKT10 cells in the brain.
    Kim TC; Park HJ; Lee SW; Park YH; Van Kaer L; Hong S
    Inflamm Res; 2024 Sep; 73(9):1511-1527. PubMed ID: 39028491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltration of invariant natural killer T cells occur and accelerate brain infarction in permanent ischemic stroke in mice.
    Wang ZK; Xue L; Wang T; Wang XJ; Su ZQ
    Neurosci Lett; 2016 Oct; 633():62-68. PubMed ID: 27637387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated immune activation with low-dose lipopolysaccharide attenuates the severity of Huntington's disease in R6/2 transgenic mice.
    Lee SW; Park HJ; Im W; Kim M; Hong S
    Anim Cells Syst (Seoul); 2018; 22(4):219-226. PubMed ID: 30460101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated α-GalCer Administration Induces a Type 2 Cytokine-Biased iNKT Cell Response and Exacerbates Atopic Skin Inflammation in Vα14
    Park HJ; Kim TC; Park YH; Lee SW; Jeon J; Park SH; Van Kaer L; Hong S
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miscarriage induced by adoptive transfer of dendritic cells and invariant natural killer T cells into mice.
    Negishi Y; Ichikawa T; Takeshita T; Takahashi H
    Eur J Immunol; 2018 Jun; 48(6):937-949. PubMed ID: 29520760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
    Hung JT; Huang JR; Yu AL
    J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
    Dufour BD; McBride JL
    Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Galactosylceramide-activated murine NK1.1(+) invariant-NKT cells in the myometrium induce miscarriages in mice.
    Ichikawa T; Negishi Y; Shimizu M; Takeshita T; Takahashi H
    Eur J Immunol; 2016 Aug; 46(8):1867-77. PubMed ID: 27198610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
    Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
    J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
    Bharhani MS; Chiu B; Na KS; Inman RD
    Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.
    Fujita H; Teng A; Nozawa R; Takamoto-Matsui Y; Katagiri-Matsumura H; Ikezawa Z; Ishii Y
    J Immunol; 2009 Jul; 183(1):254-60. PubMed ID: 19542437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.
    Chuang YH; Wang TC; Jen HY; Yu AL; Chiang BL
    J Immunol; 2011 Apr; 186(8):4687-92. PubMed ID: 21383248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
    Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
    Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists.
    Kulkarni RR; Villanueva AI; Elawadli I; Jayanth P; Read LR; Haeryfar SM; Sharif S
    Cell Immunol; 2012; 277(1-2):33-43. PubMed ID: 22795895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.